FLGTHealthcare · Diagnostics & ResearchThe 1 Wall Street analysts covering Fulgent Genetics, Inc. hold a median 12-month price target of $19 — +2.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 13 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Fulgent Genetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (81): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (35): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on FLGT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +2.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Piper Sandler | Maintains | Neutral | $15 → $19 |
| 5 May 2026 | Piper Sandler | Reiterates | Neutral | $30 → $15 |
| 5 May 2026 | Piper Sandler | Reiterates | Neutral | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 5 Aug 2025 | UBS | Upgrade | Buy | — |
| 4 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
| 6 May 2025 | Piper Sandler | Maintains | Neutral | — |
| 5 May 2025 | Raymond James | Reiterates | Outperform | — |
| 4 Mar 2025 | Piper Sandler | Maintains | Neutral | — |
| 11 Nov 2024 | Piper Sandler | Maintains | Neutral | — |
| 6 Mar 2024 | Piper Sandler | Maintains | Neutral | — |
| 7 Dec 2023 | UBS | Initiates | Neutral | — |
| 16 Oct 2023 | Piper Sandler | Maintains | Neutral | — |
| 2 Mar 2023 | Credit Suisse | Maintains | Outperform | — |
| 8 Dec 2022 | Piper Sandler | Downgrade | Neutral | — |
| 18 Nov 2022 | Raymond James | Initiates | Outperform | — |
| 14 Nov 2022 | Credit Suisse | Maintains | Outperform | — |
| 14 Nov 2022 | Piper Sandler | Maintains | Overweight | — |
| 25 Aug 2022 | Credit Suisse | Initiates | Outperform | — |
| 16 May 2022 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FLGT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 59% of US stocks
Cheaper than 85% of US stocks
Cheaper than 74% of US stocks
Higher than 37% of US stocks
Higher than 41% of US stocks
Higher than 35% of US stocks
Higher than 18% of US stocks
Higher than 14% of US stocks
Higher than 37% of US stocks
Higher than 30% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Fulgent Genetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Fulgent Genetics, Inc. released the transcript of its Q2 2026 earnings call, detailing the company's financial performance and operational results for the quarter.
Why it matters — Earnings call transcripts provide investors and analysts with direct insight into management's commentary on financial results, business trends, and forward-looking outlook.
Fulgent Genetics reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% year over year, helped by a full quarter from Bako Diagnostics and StrataDx. Management lowered its full-year revenue outlook due to lower collection rates during a transition to a new billing and revenue-cycle-management system.
Why it matters — Investors tracking FLGT would note the revenue growth from recent acquisitions as a positive, but the lowered full-year guidance signals near-term headwinds from the billing-system transition.
Fulgent Genetics reported a quarterly loss of $0.58 per share, wider than the Zacks Consensus Estimate of a $0.46 loss, and a sharp decline from earnings of $0.07 per share a year ago.
Why it matters — The results fell short of analyst expectations and reversed a year-ago profit, signaling a potential deterioration in the company's near-term financial performance.
Fulgent Genetics reported its financial results for the second quarter of 2026, with revenue of $85.4 million and a GAAP net loss of $29.5 million, or $(1.05) per share.
Why it matters — The quarterly results reveal a significant net loss, which FLGT watchers would monitor as an indicator of the company's near-term financial performance and cash burn trajectory.
The 1 Wall Street analysts covering Fulgent Genetics, Inc. have a median 12-month price target of $19, with estimates ranging from $19 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Fulgent Genetics, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fulgent Genetics, Inc. 43 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, Fulgent Genetics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (81 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +2.4% from the last close, and Ticker Nerd's factor model ranks Fulgent Genetics, Inc. 43 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Fulgent Genetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FLGT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $19 over the next 12 months.
Fulgent Genetics, Inc. returned -14.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Fulgent Genetics Inc. is a technology-based company specializing in genetic testing and precision medicine services.
The most recent item we track (Seeking Alpha, 31 July 2026): "Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript". Fulgent Genetics, Inc. released the transcript of its Q2 2026 earnings call, detailing the company's financial performance and operational results for the quarter.
Fulgent Genetics Inc. is a technology-based company specializing in genetic testing and precision medicine services. It operates a laboratory services business that provides technical laboratory testing and professional interpretation of results by licensed physicians, delivering clinically actionable diagnostic information to healthcare providers. This segment focuses on genomic diagnostics, including advanced platforms like FulgentExome for patient-centric exome analysis and Fulgent Pipeline Manager for processing genetic sequencing data. Complementing this, Fulgent Genetics Inc. maintains a therapeutic development business centered on oncology, developing drug candidates for various cancers using a proprietary nanoencapsulation and targeted therapy platform to enhance drug delivery, solubility, and efficacy. The company applies technologies such as bioinformatics, AI-driven digital pathology like Eziopath, and workflow optimization across its operations. Primarily serving the United States market, it supports physicians in areas like pathology, PCR testing, and anatomic pathology through CLIA- and CAP-accredited labs. Founded in 1996 and headquartered in El Monte, California, Fulgent Genetics Inc. integrates diagnostics and therapeutics to advance precision medicine in healthcare.
CEO Mr. Ming Hsieh · 1,315 employees · United States · https://www.fulgentgenetics.com